Singapore markets closed

Regulus Therapeutics Inc. (RGLS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.6500-0.0400 (-1.49%)
At close: 04:00PM EDT
2.6200 -0.03 (-1.13%)
After hours: 07:14PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.6900
Open2.8300
Bid2.6100 x 100
Ask2.6700 x 500
Day's range2.6400 - 2.8300
52-week range1.0800 - 3.7900
Volume406,153
Avg. volume3,249,896
Market cap173.483M
Beta (5Y monthly)1.55
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan and President & Head of Research & Development Preston Klassen, M.D., will be participating in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series hosted by Whitney Ijem on Wednesday, May 1, 2024, at 1:00 p.m. ET.

  • PR Newswire

    Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

  • PR Newswire

    Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The oversubscribed financing includes participation from new and existing institutional investors, including Adage Capital Pa